Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3219150,detection limit,"After methanol deproteinization and ethyl ether extraction under alkaline conditions as pretreatment, the detection limit for KW-3049 in plasma was 0.2 ng/ml using 0.5 ml of sample.",Sensitive radioreceptor assay of the calcium antagonist benidipine hydrochloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219150/),[ng] / [ml],0.2,1738,DB01054,Nitrendipine
,3219150,detection limit,"For the urine, 0.05 ml of urine sample was directly added to the assay system, and detection limit of drug was 1 ng/ml.",Sensitive radioreceptor assay of the calcium antagonist benidipine hydrochloride in plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3219150/),[ng] / [ml],1,1739,DB01054,Nitrendipine
,21058416,flow rate,The mobile phase used was acetonitrile and 50 mm ammonium acetate buffer at a flow rate of 1 mL/min.,Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ml] / [min],1,3720,DB01054,Nitrendipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,5.12,3721,DB01054,Nitrendipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,10.53,3722,DB01054,Nitrendipine
,21058416,retention times,"The retention times for pioglitazone, felodipine and nitrendipine were found to be 5.12, 10.53 and 7.14 min, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),min,7.14,3723,DB01054,Nitrendipine
,21058416,C(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],394.6,3724,DB01054,Nitrendipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.6,3725,DB01054,Nitrendipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],2624.2,3726,DB01054,Nitrendipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[ng] / [ml],44.4,3727,DB01054,Nitrendipine
,21058416,T(Max),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),h,5.5,3728,DB01054,Nitrendipine
,21058416,AUC(0-24),"The C(Max) , T(Max) , and AUC(0-24) of pioglitazone and felodipine from buccal tablet were found to be 394.6 ng/mL, 5.6 h, 2624.2 ng h/mL and 44.4 ng/mL, 5.5 h, 275.8 ng h/mL, respectively.",Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21058416/),[h·ng] / [ml],275.8,3729,DB01054,Nitrendipine
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],10.9,8924,DB01054,Nitrendipine
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8925,DB01054,Nitrendipine
,11736882,Cmax,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[ng] / [ml],5.0,8926,DB01054,Nitrendipine
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],60,8927,DB01054,Nitrendipine
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],15,8928,DB01054,Nitrendipine
,11736882,AUC,"Bile acids decreased the Cmax (ng ml(-1)) [control 10.9 +/- 5.8 (mean+/- s.d.), UDCA 5.0 +/- 4.7 (95% confidence interval for difference; 3.9, 7.8, P = 0.0006), CDCA (600 mg) 5.0 +/- 3.9 (2.6, 9.2, P = 0.0059)] and AUC (ng ml(-1) h) [(control; 60 +/- 36, UDCA 15 +/- 13 (20, 73, P = 0.0064), CDCA (600 mg) 19 +/- 19 (21, 63, P = 0.0038)] of nitrendipine, while elimination half-life remained unchanged.",Effect of bile acids on absorption of nitrendipine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11736882/),[h·ng] / [ml],19,8929,DB01054,Nitrendipine
,3766146,half-lives,Both myocardial accumulation and disposition pharmacokinetics of the drug showed one-compartment characteristics with half-lives of about 97 min.,"Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),min,97,10987,DB01054,Nitrendipine
,3766146,Apparent Vd,"Apparent Vd was about 480 ml/g myocardial tissue, which expresses a very pronounced binding and accumulation of felodipine in the rabbit myocardium in vitro.","Felodipine, pharmacodynamics and pharmacokinetics in the isolated rabbit heart. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3766146/),[ml] / [g],480,10988,DB01054,Nitrendipine
,17161566,oral bioavailability,Nitrendipine is an antihypertensive drug with poor oral bioavailability ranging from 10 to 20% due to the first pass metabolism.,Development and evaluation of nitrendipine loaded solid lipid nanoparticles: influence of wax and glyceride lipids on plasma pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17161566/),%,10 to 20,12507,DB01054,Nitrendipine
greater,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,93.9,20191,DB01054,Nitrendipine
,12907265,Recovery,Recovery for nifedipine was greater than 93.9% and for internal standard nitrendipine was 96.1%.,Determination of nifedipine in human plasma by solid-phase extraction and high-performance liquid chromatography: validation and application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907265/),%,96.1,20192,DB01054,Nitrendipine
,3358886,steady state plasma levels,2. Subsequently to an intravenous loading dose (0.07 mg kg-1) midazolam was infused for 6 h (0.035 mg kg-1 h-1) and steady state plasma levels between 54 to 114 micrograms l-1 were achieved.,Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[μg] / [l],54 to 114,22717,DB01054,Nitrendipine
,3358886,t 1/2,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),h,2.5,22718,DB01054,Nitrendipine
,3358886,CL,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[ml] / [min],548,22719,DB01054,Nitrendipine
,3358886,t 1/2,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),h,2.4,22720,DB01054,Nitrendipine
,3358886,CL,"5. There was also no pharmacokinetic interaction between both agents, since elimination of midazolam (t 1/2 = 2.5 +/- 0.8 h; CL = 548 +/- 143 ml min-1) was in close agreement with control values (t 1/2 = 2.4 +/- 0.6 h; CL = 512 +/- 102 ml min-1).",Lack of effect of nitrendipine on the pharmacokinetics and pharmacodynamics of midazolam during steady state. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358886/),[ml] / [min],512,22721,DB01054,Nitrendipine
,3588513,Emax,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,100,24274,DB01054,Nitrendipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,10,24275,DB01054,Nitrendipine
,3588513,IC50,"The corresponding Emax-values were about 100% and IC50-values about 10 and 65 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,65,24276,DB01054,Nitrendipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,68,24277,DB01054,Nitrendipine
,3588513,Emax,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,78,24278,DB01054,Nitrendipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,21,24279,DB01054,Nitrendipine
,3588513,IC50,"Myocardial oxygen consumption did not decrease at the lower concentrations of neither nicardipine nor nitrendipine but were at the higher levels inhibited significantly with Emax-values of about 68 and 78% and IC50-values about 21 and 136 nM, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,136,24280,DB01054,Nitrendipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,33,24281,DB01054,Nitrendipine
,3588513,Emax,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),%,56,24282,DB01054,Nitrendipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,6,24283,DB01054,Nitrendipine
,3588513,IC50,"Both drugs, but especially nitrendipine, showed a marked negative chronotropic effect (Emax 33 and 56% and IC50 6 and 81 nM, respectively).",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),nM,81,24284,DB01054,Nitrendipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,56,24285,DB01054,Nitrendipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,16,24286,DB01054,Nitrendipine
,3588513,terminal half-lives,"The terminal half-lives for the drugs were about 56, 16 and 29 min., respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),min,29,24287,DB01054,Nitrendipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],290,24288,DB01054,Nitrendipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],61,24289,DB01054,Nitrendipine
,3588513,Apparent relative volumes of drug distribution,"Apparent relative volumes of drug distribution in the myocardium which equals the average concentration ratio for the drugs between this tissue and the perfusion liquid at kinetic steady-states were about 290, 61 and 177 ml X g-1, respectively.",A comparative study of the pharmacodynamics and pharmacokinetics of nicardipine and nitrendipine in the isolated rabbit heart. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3588513/),[ml] / [g],177,24290,DB01054,Nitrendipine
,34389913,polydispersity index (PDI),The optimized NS depicted a particle size of 505.74 ± 15.48 nm with a polydispersity index (PDI) of 0.083 ± 0.006 (Fig. 1b).,"Formulation, Optimization and Evaluation of Nanoparticulate Oral Fast Dissolving Film Dosage Form of Nitrendipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34389913/),,0.083,32295,DB01054,Nitrendipine
,34389913,tens,"The developed NIT N-ODF exhibited thickness (0.148 ± 0.008 mm), folding endurance (280.33 ± 5.51 times), surface pH (6.86 ± 0.05), tensile strength (8.25 ± 0.13 kg/cm2), % elongation (63.5 ± 1.97%), and disintegration time (24.60 ± 1.31 s) to be within the standard intended limit.","Formulation, Optimization and Evaluation of Nanoparticulate Oral Fast Dissolving Film Dosage Form of Nitrendipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34389913/),kg,8.25,32296,DB01054,Nitrendipine
,34389913,%,"The developed NIT N-ODF exhibited thickness (0.148 ± 0.008 mm), folding endurance (280.33 ± 5.51 times), surface pH (6.86 ± 0.05), tensile strength (8.25 ± 0.13 kg/cm2), % elongation (63.5 ± 1.97%), and disintegration time (24.60 ± 1.31 s) to be within the standard intended limit.","Formulation, Optimization and Evaluation of Nanoparticulate Oral Fast Dissolving Film Dosage Form of Nitrendipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34389913/),,63.5,32297,DB01054,Nitrendipine
,34389913,disintegration time,"The developed NIT N-ODF exhibited thickness (0.148 ± 0.008 mm), folding endurance (280.33 ± 5.51 times), surface pH (6.86 ± 0.05), tensile strength (8.25 ± 0.13 kg/cm2), % elongation (63.5 ± 1.97%), and disintegration time (24.60 ± 1.31 s) to be within the standard intended limit.","Formulation, Optimization and Evaluation of Nanoparticulate Oral Fast Dissolving Film Dosage Form of Nitrendipine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34389913/),s,24.60,32298,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),,1.29,34555,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,1.83,34556,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,1.93,34557,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,1.30,34558,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,2.04,34559,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,0.64,34560,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,1.41,34561,DB01054,Nitrendipine
,23774663,time for maximum concentration (Tmax),"After oral administration, the plasma concentration-time curves showed that the time for maximum concentration (Tmax) was 1.29 for coumarin, 1.83 for isopsoralen, 1.93 for psoralen, 1.30 for xanthotoxin, 2.04 for bergapten, 0.64 for osthole, 1.41 for imperatorin and 0.51 h for oxypeucedanin.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),h,0.51,34562,DB01054,Nitrendipine
<,23774663,maximum plasma concentration (Cmax),"The plasma concentration of the eight coumarins was low, with a mean maximum plasma concentration (Cmax) <6.41 μg/mL.",Pharmacokinetic study of eight coumarins of Radix Angelicae Dahuricae in rats by gas chromatography-mass spectrometry. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23774663/),[μg] / [ml],6.41,34563,DB01054,Nitrendipine
,2713213,zero-order in vitro release,In nine healthy male subjects the kinetics of nitrendipine were assessed after i.v. administration and its absorption profile was studied when given by a tablet formulation and by an osmotic pumping device (Osmet) with a zero-order in vitro release of 2.62 +/- 0.19 mg h-1 for 13 h.,Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),[mg] / [h],2.62,37612,DB01054,Nitrendipine
,2713213,terminal elimination half-life,"3. After i.v. nitrendipine, the plasma concentration declined triexponentially with a mean terminal elimination half-life of 11.7 +/- 5.4 h.",Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),h,11.7,37613,DB01054,Nitrendipine
,2713213,systemic plasma clearance,The mean systemic plasma clearance was 1.47 +/- 0.22 l min-1.,Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),[l] / [min],1.47,37614,DB01054,Nitrendipine
,2713213,plateau concentration,The mean plateau concentration was 2.63 +/- 1.31 ng ml-1 and the duration of this plateau was 10.7 +/- 3.2 h.,Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),[ng] / [ml],2.63,37615,DB01054,Nitrendipine
,2713213,duration of this plateau,The mean plateau concentration was 2.63 +/- 1.31 ng ml-1 and the duration of this plateau was 10.7 +/- 3.2 h.,Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),h,10.7,37616,DB01054,Nitrendipine
,2713213,bioavailability,"5. The mean bioavailability of nitrendipine from the Osmet (8.2 +/- 1.6%) was lower than from the tablet (11.1 +/- 4.5%), which is probably due to release of nitrendipine in lower parts of the G.I. tract where absorption is not or less possible.",Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),%,8.2,37617,DB01054,Nitrendipine
,2713213,bioavailability,"5. The mean bioavailability of nitrendipine from the Osmet (8.2 +/- 1.6%) was lower than from the tablet (11.1 +/- 4.5%), which is probably due to release of nitrendipine in lower parts of the G.I. tract where absorption is not or less possible.",Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2713213/),%,11.1,37618,DB01054,Nitrendipine
,17339138,ch,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44539,DB01054,Nitrendipine
,17339138,running time,The method had a chromatographic running time of approximately 2.5 min and linear calibration curves over the concentrations of 0.5-100 ng/mL for NIF and DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44540,DB01054,Nitrendipine
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,81.3-89.1,44541,DB01054,Nitrendipine
,17339138,recoveries,The recoveries of the one-step liquid extraction method were 81.3-89.1% for NIF and 71.6-80.4% for DNIF.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),%,71.6-80.4,44542,DB01054,Nitrendipine
,17339138,running time,These results indicated that the developed LC/MS/MS method was efficient with a significantly shorter running time (2.5 min) for NIF and DNIF compared to those methods previously reported in the literature.,Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17339138/),min,2.5,44543,DB01054,Nitrendipine
,22531846,T(max),"In the in vivo study, the C(max) of nitrendipine remained the same, however, the T(max) delayed from 0.75 h to 1.5 h with the chitosan modified nanocrystals.",A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531846/),h,0.75,53782,DB01054,Nitrendipine
,22531846,T(max),"In the in vivo study, the C(max) of nitrendipine remained the same, however, the T(max) delayed from 0.75 h to 1.5 h with the chitosan modified nanocrystals.",A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22531846/),h,1.5,53783,DB01054,Nitrendipine
,2054271,systemic clearance,The systemic clearance after i.v. administration in patients with renal impairment (18.2 +/- 6.1 ml min-1 kg-1) was similar to that observed in healthy volunteers.,"Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054271/),[ml] / [kg·min],18.2,56619,DB01054,Nitrendipine
,2054271,bioavailability,Despite complete absorption of drug from the tablet the bioavailability of the parent compound was 21.2 +/- 12.5%.,"Pharmacokinetics, bioavailability, metabolism and acute and chronic antihypertensive effects of nitrendipine in patients with chronic renal failure and moderate to severe hypertension. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2054271/),%,21.2,56620,DB01054,Nitrendipine
,3160527,t1/2,The mean nitrendipine t1/2 was 2.8 +/- 2.1 hours and that of the metabolite was 3.4 +/- 3.9 hours.,Nitrendipine kinetics in normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3160527/),h,2.8,59160,DB01054,Nitrendipine
,3160527,t1/2,The mean nitrendipine t1/2 was 2.8 +/- 2.1 hours and that of the metabolite was 3.4 +/- 3.9 hours.,Nitrendipine kinetics in normal and impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3160527/),h,3.4,59161,DB01054,Nitrendipine
,6085386,relative bioavailability,"Although relative bioavailability of the tablets ranged from 58.0 to 69.9%, there was no statistically significant difference in the area under the curve among the doses.",Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085386/),%,58.0 to 69.9,60220,DB01054,Nitrendipine
,16207605,relative bioavailabilities,"The relative bioavailabilities of test formulations were intensively improved compared with the domestic nitrendipine tablets, while the ratio is in a range of 80-120% in comparison with Baypress nitrendipine tablets.",In vivo evaluation of two novel controlled-release nitrendipine formulations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207605/),%,80-120,62464,DB01054,Nitrendipine
,16207605,ratio,"The relative bioavailabilities of test formulations were intensively improved compared with the domestic nitrendipine tablets, while the ratio is in a range of 80-120% in comparison with Baypress nitrendipine tablets.",In vivo evaluation of two novel controlled-release nitrendipine formulations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16207605/),%,80-120,62465,DB01054,Nitrendipine
,18082350,flow rate,"The separation was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with water and acetonitrile (both containing 0.1% formic acid) as the mobile phase under gradient conditions at a flow rate of 0.35 ml/min.",Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18082350/),[ml] / [min],0.35,66471,DB01054,Nitrendipine
,1540491,AUC,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[h·ng] / [ml],29.9,73602,DB01054,Nitrendipine
,1540491,AUC,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[h·ng] / [ml],123.8,73603,DB01054,Nitrendipine
,1540491,bioavailability,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),%,10.7,73604,DB01054,Nitrendipine
,1540491,bioavailability,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),%,44.6,73605,DB01054,Nitrendipine
,1540491,Cmax,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],14.4,73606,DB01054,Nitrendipine
,1540491,Cmax,"2. After administration of the enantiomers pronounced differences in AUC (R: 29.9 +/- 20.1; S: 123.8 +/- 63.7 ng ml-1 h; P less than 0.05), bioavailability (R: 10.7 +/- 7.4%; S: 44.6 +/- 23.1%; P less than 0.05) and Cmax (R: 14.4 +/- 7.7; S: 72.5 +/- 40.5 ng ml-1; P less than 0.05) were observed between R- and S-nitrendipine.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],72.5,73607,DB01054,Nitrendipine
,1540491,bioavailability,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),%,10.7,73608,DB01054,Nitrendipine
,1540491,bioavailability,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),%,22.1,73609,DB01054,Nitrendipine
,1540491,dose normal,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],15.0,73610,DB01054,Nitrendipine
,1540491,dose normal,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],29.5,73611,DB01054,Nitrendipine
,1540491,AUC,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],15.0,73612,DB01054,Nitrendipine
,1540491,AUC,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],29.5,73613,DB01054,Nitrendipine
,1540491,Cmax,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],7.2,73614,DB01054,Nitrendipine
,1540491,Cmax,"In contrast, bioavailability (R: 10.7% R,S: 22.1%) and dose normalized AUC (R: 15.0; R,S: 29.5 ng ml-1 h and Cmax (R: 7.2; R,S: 16.8 ng ml-1) of R-nitrendipine were doubled following R,S- as compared with R-nitrendipine administration.",Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[ng] / [ml],16.8,73615,DB01054,Nitrendipine
,1540491,t1/2,t1/2 (R: 9.8; S: 9.1 h) and tmax were not different between the enantiomers nor were the values different after administration of the enantiomers or racemate.,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),h,9.8,73616,DB01054,Nitrendipine
,1540491,t1/2,t1/2 (R: 9.8; S: 9.1 h) and tmax were not different between the enantiomers nor were the values different after administration of the enantiomers or racemate.,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),h,9.1,73617,DB01054,Nitrendipine
,1540491,fraction unbound in serum,The fraction unbound in serum of R-nitrendipine was 0.0098 +/- 0.0032 (s.d.) and that of S-nitrendipine was 0.0083 +/- 0.0015 (s.d.).,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),,0.0098,73618,DB01054,Nitrendipine
,1540491,fraction unbound in serum,The fraction unbound in serum of R-nitrendipine was 0.0098 +/- 0.0032 (s.d.) and that of S-nitrendipine was 0.0083 +/- 0.0015 (s.d.).,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),,0.0083,73619,DB01054,Nitrendipine
,1540491,AUC,3. The AUC values of the major pyridine metabolite M1 were similar after administration of R- and S-nitrendipine (S: 114.7 +/- 48.5; R: 71.7 +/- 29.9 ng ml-1 h).,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[h·ng] / [ml],114.7,73620,DB01054,Nitrendipine
,1540491,AUC,3. The AUC values of the major pyridine metabolite M1 were similar after administration of R- and S-nitrendipine (S: 114.7 +/- 48.5; R: 71.7 +/- 29.9 ng ml-1 h).,Use of pseudoracemic nitrendipine to elucidate the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540491/),[h·ng] / [ml],71.7,73621,DB01054,Nitrendipine
,3435690,terminal elimination half-life,2. The mean terminal elimination half-life was 8.3 +/- 3.2 h (range 3.4 to 16 h) with no differences between the intravenous and oral route of administration.,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),h,8.3,95046,DB01054,Nitrendipine
,3435690,Total plasma clearance,Total plasma clearance averaged 18.7 +/- 0.6 ml min-1 kg-1 and volume of distribution at steady state 5.4 +/- 2.4 1 kg-1.,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),[ml] / [kg·min],18.7,95047,DB01054,Nitrendipine
,3435690,volume of distribution at steady state,Total plasma clearance averaged 18.7 +/- 0.6 ml min-1 kg-1 and volume of distribution at steady state 5.4 +/- 2.4 1 kg-1.,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),[1] / [kg],5.4,95048,DB01054,Nitrendipine
,3435690,percentage of dose absorbed,3. Following oral administration of nitrendipine solution the percentage of dose absorbed was 88.4 +/- 16.0% based on urinary excretion of metabolites.,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),%,88.4,95049,DB01054,Nitrendipine
,3435690,absolute bioavailability,"Despite its almost complete absorption, absolute bioavailability of the solution was only 22.6 +/- 6.7% due to extensive presystemic elimination.","Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),%,22.6,95050,DB01054,Nitrendipine
,3435690,bioavailability,The bioavailability of the commercial tablet relative to the solution was 82.2 +/- 20.3%.,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),%,82.2,95051,DB01054,Nitrendipine
,3435690,fraction unbound,5. Binding of nitrendipine to plasma proteins was high with a fraction unbound of only 0.02 +/- 0.012 (range 0.011 to 0.036).,"Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3435690/),,0.02,95052,DB01054,Nitrendipine
,8135031,elimination-half-life,"Therefore the Ca-antagonists of the so-called 2nd generation (e.g. Amlodipine, Felodipine, Isradipine, Nitrendipine, Nicardipine, Nimodipine, Nisoldipine) tend to longer elimination-half-lives; Amlodipin is an exception with an elimination-half-life of 30 hours on the average.",[Principles of the pharmacokinetics and pharmacodynamics of calcium antagonists]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8135031/),h,30,96381,DB01054,Nitrendipine
,2753073,peak concentrations,Nitrendipine was excreted in breast milk at peak concentrations ranging from 4.3 to 6.5 ng/ml 1-2 h after acute dosing while its inactive pyridine metabolite ranged from 6.9 to 11.9 ng.,Nitrendipine in human plasma and breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753073/),[ng] / [ml],4.3 to 6.5,99574,DB01054,Nitrendipine
,2753073,peak concentrations,Nitrendipine was excreted in breast milk at peak concentrations ranging from 4.3 to 6.5 ng/ml 1-2 h after acute dosing while its inactive pyridine metabolite ranged from 6.9 to 11.9 ng.,Nitrendipine in human plasma and breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753073/),ng,6.9 to 11.9,99575,DB01054,Nitrendipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],63.2,109408,DB01054,Nitrendipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],46.4,109409,DB01054,Nitrendipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),[fmol] / [mg],66.8,109410,DB01054,Nitrendipine
,12839868,Maximum binding,6. Maximum binding of (3)H-nitrendipine to cardiac cell membrane was significantly reduced from 63.2+/-2.5 fmol mg(-1) protein in controls to 46.4+/-2.0 in acute inflammation and from 66.8+/-2.2 fmol mg(-1) protein in controls to 42.2+/-2.0 in chronic inflammation.,"Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12839868/),,42.2,109411,DB01054,Nitrendipine
,2468876,terminal half-life,"The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,8,109841,DB01054,Nitrendipine
,2468876,terminal half-life,"The terminal half-life is on average 8 h, and thus substantially longer than the terminal half-life of 2-3 h for nifedipine.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,2-3,109842,DB01054,Nitrendipine
,2468876,bioavailability,"Despite its almost complete absorption, bioavailability is on average 15-25% and shows great interindividual variability ranging from 7 to 40%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,15-25,109843,DB01054,Nitrendipine
,2468876,systemic plasma clearance,The systemic plasma clearance of the drug is on average 18 ml/min/kg and thus approaches the liver blood flow.,Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),[ml] / [kg·min],18,109844,DB01054,Nitrendipine
,2468876,half-life,"In patients with liver cirrhosis, the half-life is prolonged to 19.6 h, the total plasma clearance is decreased by 50%, and the bioavailability is more than doubled to 54%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,19.6,109845,DB01054,Nitrendipine
,2468876,bioavailability,"In patients with liver cirrhosis, the half-life is prolonged to 19.6 h, the total plasma clearance is decreased by 50%, and the bioavailability is more than doubled to 54%.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,54,109846,DB01054,Nitrendipine
,2468876,terminal elimination half-life,Systemic clearance is not changed but the terminal elimination half-life is slightly prolonged to 10.5 h.,Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),h,10.5,109847,DB01054,Nitrendipine
,2468876,Bioavailability,"Bioavailability, which is 21.2%, is not grossly altered in renal failure.",Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468876/),%,21.2,109848,DB01054,Nitrendipine
,3396260,Cmax,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [l],17,113908,DB01054,Nitrendipine
,3396260,Cmin,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [l],5,113909,DB01054,Nitrendipine
,3396260,AUC,"Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L.h) were 3 times higher in the elderly than in the young subjects.",Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[nM] / [h·l],82,113910,DB01054,Nitrendipine
,3396260,Systemic availability,Systemic availability was about 15% in both groups.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),%,15,113911,DB01054,Nitrendipine
,3396260,Plasma clearance (CL),Plasma clearance (CL) was reduced from 56.1 L/h in the young to 25.4 L/h in the elderly.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[l] / [h],56.1,113912,DB01054,Nitrendipine
,3396260,Plasma clearance (CL),Plasma clearance (CL) was reduced from 56.1 L/h in the young to 25.4 L/h in the elderly.,Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396260/),[l] / [h],25.4,113913,DB01054,Nitrendipine
,1564134,Absolute sodium excretion,"Absolute sodium excretion increased by 25.9% from 0.27 +/- 0.03 mmol/min to 0.34 +/- 0.02 mmol/min (P = .02), and fractional sodium excretion increased by 32.3% from 18.9 +/- 3.0% to 25.0 +/- 1.9% (P = .03) after nitrendipine, but both were unchanged after placebo.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),[mM] / [min],0.27,120609,DB01054,Nitrendipine
,1564134,Absolute sodium excretion,"Absolute sodium excretion increased by 25.9% from 0.27 +/- 0.03 mmol/min to 0.34 +/- 0.02 mmol/min (P = .02), and fractional sodium excretion increased by 32.3% from 18.9 +/- 3.0% to 25.0 +/- 1.9% (P = .03) after nitrendipine, but both were unchanged after placebo.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),[mM] / [min],0.34,120610,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of magnesium increased after both placebo and nitrendipine administration, from 5.0 +/- 0.6% to 6.8 +/- 0.7% (P = .027) and 5.7 +/- 0.8% to 8.8 +/- 1.0% (P = .006), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,5.0,120611,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of magnesium increased after both placebo and nitrendipine administration, from 5.0 +/- 0.6% to 6.8 +/- 0.7% (P = .027) and 5.7 +/- 0.8% to 8.8 +/- 1.0% (P = .006), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,6.8,120612,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of magnesium increased after both placebo and nitrendipine administration, from 5.0 +/- 0.6% to 6.8 +/- 0.7% (P = .027) and 5.7 +/- 0.8% to 8.8 +/- 1.0% (P = .006), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,5.7,120613,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of magnesium increased after both placebo and nitrendipine administration, from 5.0 +/- 0.6% to 6.8 +/- 0.7% (P = .027) and 5.7 +/- 0.8% to 8.8 +/- 1.0% (P = .006), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,8.8,120614,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of phosphate also increased after both placebo and nitrendipine, from 9.5 +/- 2.3% to 12.9 +/- 3.9% (P = .05) and 9.7 +/- 1.7% to 14.2 +/- 1.9% (P = .002), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,9.5,120615,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of phosphate also increased after both placebo and nitrendipine, from 9.5 +/- 2.3% to 12.9 +/- 3.9% (P = .05) and 9.7 +/- 1.7% to 14.2 +/- 1.9% (P = .002), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,12.9,120616,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of phosphate also increased after both placebo and nitrendipine, from 9.5 +/- 2.3% to 12.9 +/- 3.9% (P = .05) and 9.7 +/- 1.7% to 14.2 +/- 1.9% (P = .002), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,9.7,120617,DB01054,Nitrendipine
,1564134,Fractional excretion,"Fractional excretion of phosphate also increased after both placebo and nitrendipine, from 9.5 +/- 2.3% to 12.9 +/- 3.9% (P = .05) and 9.7 +/- 1.7% to 14.2 +/- 1.9% (P = .002), respectively.",Nitrendipine and renal tubular function in human volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1564134/),%,14.2,120618,DB01054,Nitrendipine
,1712269,terminal half-life,"In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712269/),h,30 to 50,120675,DB01054,Nitrendipine
,30993887,flow rate,"The chromatographic separation was achieved on an ACQUITY UPC2 ™ BEH 2-EP column, and a gradient elution program was applied at a flow rate of 1.5 mL/min.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ml] / [min],1.5,127221,DB01054,Nitrendipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],279.28,127222,DB01054,Nitrendipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],265.13,127223,DB01054,Nitrendipine
,30993887,peak concentration,"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[min·ng] / [ml],25608.00,127224,DB01054,Nitrendipine
,30993887,area under concentration-time curve (0-720 min),"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[ng] / [ml],265.13,127225,DB01054,Nitrendipine
,30993887,area under concentration-time curve (0-720 min),"The peak concentration and area under concentration-time curve (0-720 min) values of the test and reference formulations were 279.28 ± 211.46 and 265.13 ± 149.26 ng/mL, 25608.00 ± 17553.65 and 28553.67 ± 20207.92 ng·min/mL, respectively.",Development and optimization of a supercritical fluid chromatography tandem mass spectrometry method for the high-throughput determination of nimodipine in beagle plasma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30993887/),[min·ng] / [ml],28553.67,127226,DB01054,Nitrendipine
,2253647,absolute bioavailability,"After intravenous and oral doses, absolute bioavailability was calculated to be 18.7%.",Evaluation of first pass effect and biliary excretion of diperdipine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253647/),%,18.7,129776,DB01054,Nitrendipine
up to,2253647,bioavailable fraction,"After intraportal administration, the bioavailable fraction of diperdipine was increasing up to 44.3% suggesting a prehepatic site of loss of the drug.",Evaluation of first pass effect and biliary excretion of diperdipine in the dog. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2253647/),%,44.3,129777,DB01054,Nitrendipine
greater,3042243,plasma protein binding,Three of the 8 dihydropyridines have been reported to have plasma protein binding greater than 90%.,Pharmacokinetics of calcium antagonists under development. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3042243/),%,90,134432,DB01054,Nitrendipine
,3327676,elimination half-life,The mean elimination half-life of felodipine is approximately 25h.,Clinical pharmacokinetics of felodipine. A summary. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),h,25,140911,DB01054,Nitrendipine
,3327676,volume of distribution,"The volume of distribution of felodipine is about 10 L/kg, implying that less than 1% of the amount of drug in the body is localised in the blood.",Clinical pharmacokinetics of felodipine. A summary. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [kg],10,140912,DB01054,Nitrendipine
,3327676,total clearance from the blood,"Mean total clearance from the blood is 1 to 1.5 L/min and, therefore, felodipine is considered a high clearance drug.",Clinical pharmacokinetics of felodipine. A summary. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3327676/),[l] / [min],1 to 1.5,140913,DB01054,Nitrendipine
,1342209,area under the curve for 24-h (AUC0-24),"3. Ranitidine coadministration increased the area under the curve for 24-h (AUC0-24) plasma concentration vs time, from 49.07 +/- 6.28 micrograms.h/l to 82.35 +/- 2.57 micrograms.h/l (P < 0.01).",Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[h·μg] / [l],49.07,142366,DB01054,Nitrendipine
,1342209,area under the curve for 24-h (AUC0-24),"3. Ranitidine coadministration increased the area under the curve for 24-h (AUC0-24) plasma concentration vs time, from 49.07 +/- 6.28 micrograms.h/l to 82.35 +/- 2.57 micrograms.h/l (P < 0.01).",Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[h·μg] / [l],82.35,142367,DB01054,Nitrendipine
,1342209,total body clearance,This significant increase caused a reduction in total body clearance from 2008.33 +/- 246.33 to 1284.00 +/- 182.16 ml/min (P < 0.002).,Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[ml] / [min],2008.33,142368,DB01054,Nitrendipine
,1342209,total body clearance,This significant increase caused a reduction in total body clearance from 2008.33 +/- 246.33 to 1284.00 +/- 182.16 ml/min (P < 0.002).,Ranitidine increases the bioavailability of nitrendipine in patients with arterial hypertension. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1342209/),[ml] / [min],1284.00,142369,DB01054,Nitrendipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,94,142680,DB01054,Nitrendipine
,16920316,analytical recovery,The analytical recovery was 94% for nitrendipine and 89% for its pyridine metabolite M1.,Simultaneous determination of nitrendipine and one of its metabolites in plasma samples by gas chromatography with electron-capture detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16920316/),%,89,142681,DB01054,Nitrendipine
,25984962,AUC(0-12),"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[ngh] / [ml],250.2,146168,DB01054,Nitrendipine
,25984962,ClT/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),[l] / [h],89.2,146169,DB01054,Nitrendipine
,25984962,Vd/F,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),l,600.0,146170,DB01054,Nitrendipine
,25984962,t1/2,"The estimated pharmacokinetic parameters of nifedipine showed a mean AUC(0-12) of 250.2ngh/mL, ClT/F of 89.2L/h, Vd/F of 600.0L and t1/2 5.1h.",Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),h,5.1,146171,DB01054,Nitrendipine
,25984962,amniotic fluid/plasma concentration ratio,The mean amniotic fluid/plasma concentration ratio was 0.05.,Analysis of nifedipine in human plasma and amniotic fluid by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics in hypertensive pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25984962/),,0.05,146172,DB01054,Nitrendipine
,3593901,systemic availability,The systemic availability varied between 10 and 23 per cent.,"Pharmacokinetic and pharmacodynamic studies of felodipine in healthy subjects after various single, oral and intravenous doses. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3593901/),%,10 and 23,154125,DB01054,Nitrendipine
,11748687,overall extraction recoveries,"The overall extraction recoveries of NIT and DNIT were determined to be about 75% and 78% on average, respectively.",Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),%,75,154257,DB01054,Nitrendipine
,11748687,overall extraction recoveries,"The overall extraction recoveries of NIT and DNIT were determined to be about 75% and 78% on average, respectively.",Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),%,78,154258,DB01054,Nitrendipine
,11748687,ch,The chromatographic run time was approximately 3 min.,Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),min,3,154259,DB01054,Nitrendipine
,11748687,run time,The chromatographic run time was approximately 3 min.,Quantitative determination of nitrendipine and its metabolite dehydronitrendipine in human plasma using liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748687/),min,3,154260,DB01054,Nitrendipine
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,5.0,160632,DB01054,Nitrendipine
,17236247,retention times,"The retention times of nitrendipine and internal standard (felodipine) were 5.0 min and 7.5 min, respectively.",Development and validation of a reversed-phase HPLC method for determination of nitrendipine in rat plasma: application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236247/),min,7.5,160633,DB01054,Nitrendipine
lower,2468869,steady-state plasma concentrations,"Twenty-two days after beginning the study, steady-state plasma concentrations were lower than 1.0 microgram/L in one patient without liver disease and in seven patients with chronic liver diseases, in contrast to three patients with alcoholic cirrhosis (5.5, 1.3, and 2.9 micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],1.0,163977,DB01054,Nitrendipine
,2468869,steady-state plasma concentrations,"Twenty-two days after beginning the study, steady-state plasma concentrations were lower than 1.0 microgram/L in one patient without liver disease and in seven patients with chronic liver diseases, in contrast to three patients with alcoholic cirrhosis (5.5, 1.3, and 2.9 micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],5.5,163978,DB01054,Nitrendipine
,2468869,steady-state plasma concentrations,"Twenty-two days after beginning the study, steady-state plasma concentrations were lower than 1.0 microgram/L in one patient without liver disease and in seven patients with chronic liver diseases, in contrast to three patients with alcoholic cirrhosis (5.5, 1.3, and 2.9 micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],1.3,163979,DB01054,Nitrendipine
,2468869,steady-state plasma concentrations,"Twenty-two days after beginning the study, steady-state plasma concentrations were lower than 1.0 microgram/L in one patient without liver disease and in seven patients with chronic liver diseases, in contrast to three patients with alcoholic cirrhosis (5.5, 1.3, and 2.9 micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],2.9,163980,DB01054,Nitrendipine
,2468869,maximum concentration (Cmax),The maximum concentration (Cmax) was 2.3 micrograms/L in the patient without liver disease and 8.3 +/- 3.9 micrograms/L in the hepatic patients.,Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],2.3,163981,DB01054,Nitrendipine
,2468869,maximum concentration (Cmax),The maximum concentration (Cmax) was 2.3 micrograms/L in the patient without liver disease and 8.3 +/- 3.9 micrograms/L in the hepatic patients.,Disposition of nitrendipine in patients with chronic liver diseases. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[μg] / [l],8.3,163982,DB01054,Nitrendipine
,2468869,elimination half-life,"The elimination half-life was prolonged in three of five patients with cirrhosis of the liver (35, 67, and 43 h), whereas in the other patients the half-life was in a normal range (4.2-21.3 h).",Disposition of nitrendipine in patients with chronic liver diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),h,35,163983,DB01054,Nitrendipine
,2468869,elimination half-life,"The elimination half-life was prolonged in three of five patients with cirrhosis of the liver (35, 67, and 43 h), whereas in the other patients the half-life was in a normal range (4.2-21.3 h).",Disposition of nitrendipine in patients with chronic liver diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),h,67,163984,DB01054,Nitrendipine
,2468869,elimination half-life,"The elimination half-life was prolonged in three of five patients with cirrhosis of the liver (35, 67, and 43 h), whereas in the other patients the half-life was in a normal range (4.2-21.3 h).",Disposition of nitrendipine in patients with chronic liver diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),h,43,163985,DB01054,Nitrendipine
,2468869,half-life,"The elimination half-life was prolonged in three of five patients with cirrhosis of the liver (35, 67, and 43 h), whereas in the other patients the half-life was in a normal range (4.2-21.3 h).",Disposition of nitrendipine in patients with chronic liver diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),h,4.2-21.3,163986,DB01054,Nitrendipine
,2468869,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was enhanced in three patients with liver cirrhosis (387, 69, and 126 h/micrograms/L); in the other seven hepatic patients, results were normal (35-49 h/micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[h] / [l·μg],387,163987,DB01054,Nitrendipine
,2468869,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was enhanced in three patients with liver cirrhosis (387, 69, and 126 h/micrograms/L); in the other seven hepatic patients, results were normal (35-49 h/micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[h] / [l·μg],69,163988,DB01054,Nitrendipine
,2468869,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was enhanced in three patients with liver cirrhosis (387, 69, and 126 h/micrograms/L); in the other seven hepatic patients, results were normal (35-49 h/micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[h] / [l·μg],126,163989,DB01054,Nitrendipine
,2468869,area under the concentration-time curve (AUC),"The area under the concentration-time curve (AUC) was enhanced in three patients with liver cirrhosis (387, 69, and 126 h/micrograms/L); in the other seven hepatic patients, results were normal (35-49 h/micrograms/L).",Disposition of nitrendipine in patients with chronic liver diseases. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468869/),[h] / [l·μg],35-49,163990,DB01054,Nitrendipine
greater,20704460,recovery,"The limit of quantitation for NF was 5 ng/mL in serum, and the recovery was greater than 90%.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),%,90,164908,DB01054,Nitrendipine
,20704460,Cmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[μg] / [l],320.2,164909,DB01054,Nitrendipine
,20704460,Tmax,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,3.2,164910,DB01054,Nitrendipine
,20704460,t1/2,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,6.60,164911,DB01054,Nitrendipine
,20704460,AUC0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.03,164912,DB01054,Nitrendipine
,20704460,AUC0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),[h·mg] / [l],2.50,164913,DB01054,Nitrendipine
,20704460,MRT0-24,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,8.57,164914,DB01054,Nitrendipine
,20704460,MRT0-∞,"The mean Cmax was 320.2 ± 71.3 μg/L, the mean Tmax was 3.2 ± 0.5 hours, the mean t1/2 was 6.60 ± 2.17 hours, the mean AUC0-24 was 2.03 ± 0.25 mg h/L, the mean AUC0-∞ was 2.50 ± 0.36 mg h/L, the mean MRT0-24 was 8.57 ± 0.19 hours, and the mean MRT0-∞ was 15.2 ± 1.8 hours.",Pharmacokinetics of a novel nifedipine and pH-sensitive N-succinyl chitosan/alginate hydrogel bead in rabbits. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20704460/),h,15.2,164915,DB01054,Nitrendipine
,3443058,maximal felodipine plasma concentration,"At steady state, the maximal felodipine plasma concentration was 25.2 +/- 1.5 nmol/L and occurred 1.3 +/- 0.2 (range 1 to 3) hours after drug intake.",Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443058/),[nM] / [l],25.2,167674,DB01054,Nitrendipine
,3443058,maximal felodipine plasma concentration,"After 2 weeks' treatment, the maximal felodipine plasma concentration was 23.3 +/- 2.7 nmol/L and was reached 4.4 +/- 0.5 (range 3 to 7) hours after each dose.",Comparison of antihypertensive effect and pharmacokinetics of conventional and extended release felodipine tablets in patients with arterial hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443058/),[nM] / [l],23.3,167675,DB01054,Nitrendipine
,2532460,terminal half-life,"In clinical pharmacology studies cilazapril, after its bioactivation to cilazaprilat, was characterized as a potent, reversible angiotensin-converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532460/),h,30 to 50,171142,DB01054,Nitrendipine
,3443063,Plasma half-life,"Plasma half-life in the 4- to 10-hour period of felodipine was 5.5 hours after a 10mg single dose, and 12 hours after 10mg bid.",Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443063/),h,5.5,171648,DB01054,Nitrendipine
,3443063,Plasma half-life,"Plasma half-life in the 4- to 10-hour period of felodipine was 5.5 hours after a 10mg single dose, and 12 hours after 10mg bid.",Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3443063/),h,12,171649,DB01054,Nitrendipine
,3677507,systemic availability,"The systemic availability of felodipine after the acute dose was 15%, and at steady state 12% (N.S.), with a 3-fold variation between patients.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),%,15,172381,DB01054,Nitrendipine
,3677507,systemic availability,"The systemic availability of felodipine after the acute dose was 15%, and at steady state 12% (N.S.), with a 3-fold variation between patients.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),%,12,172382,DB01054,Nitrendipine
,3677507,plasma clearance,The mean plasma clearance was 0.6 L/h.,Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),[l] / [h],0.6,172383,DB01054,Nitrendipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.4,172384,DB01054,Nitrendipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.2,172385,DB01054,Nitrendipine
,3677507,half-life,"The half-life measured in the 4- to 10-h interval after dose was about the same: 3.4, 3.2, and 3.3 h after the i.v. dose, the acute oral dose, and at steady state, respectively.",Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,3.3,172386,DB01054,Nitrendipine
,3677507,terminal half-life,The mean terminal half-life was 24.5 h after the oral dose at steady state.,Pharmacokinetics and haemodynamic effects of felodipine as monotherapy in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3677507/),h,24.5,172387,DB01054,Nitrendipine
,20417274,zeta potential,"The particle size and zeta potential of nanocrystals were 209 nm (+/- 9 nm) and -13.9 mV (+/-1.9 mV), respectively.",Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20417274/),mv,-,173587,DB01054,Nitrendipine
,20417274,zeta potential,"The particle size and zeta potential of nanocrystals were 209 nm (+/- 9 nm) and -13.9 mV (+/-1.9 mV), respectively.",Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20417274/),mv,13.9,173588,DB01054,Nitrendipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],26,173989,DB01054,Nitrendipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],7.5,173990,DB01054,Nitrendipine
,3776550,oral plasma clearance,"The same species difference was observed in vivo for the oral plasma clearance which was; rat 26 1/hr/kg, dog 7.5 1/hr/kg and man 4.3 1/hr/kg.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),[1] / [h·kg],4.3,173991,DB01054,Nitrendipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.80,173992,DB01054,Nitrendipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.83,173993,DB01054,Nitrendipine
,3776550,extraction ratios,"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84.","In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man. ",E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3776550/),,0.84,173994,DB01054,Nitrendipine
,3214443,terminal half-lives,The radioactivity was eliminated from the tissues with terminal half-lives lying between 52 (plasma) and 360 h (muscle).,The pharmacokinetics of nitrendipine. Distribution to and elimination from organs and tissues of rats and dogs after single or repeated administration of [14C]nitrendipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214443/),h,52,182486,DB01054,Nitrendipine
,3214443,terminal half-lives,The radioactivity was eliminated from the tissues with terminal half-lives lying between 52 (plasma) and 360 h (muscle).,The pharmacokinetics of nitrendipine. Distribution to and elimination from organs and tissues of rats and dogs after single or repeated administration of [14C]nitrendipine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214443/),h,360,182487,DB01054,Nitrendipine
,3214443,half-lives,"The half-lives were increased by 20 to 70%, lying between 2 and 15 days.",The pharmacokinetics of nitrendipine. Distribution to and elimination from organs and tissues of rats and dogs after single or repeated administration of [14C]nitrendipine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214443/),d,2 and 15,182488,DB01054,Nitrendipine
,17090399,size,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,101.9,182785,DB01054,Nitrendipine
,17090399,size,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,123.5,182786,DB01054,Nitrendipine
,17090399,zeta potential,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),nm,123.5,182787,DB01054,Nitrendipine
,17090399,zeta potential,"Average size and zeta potential of SLNs of different lipids, with and without charge modifiers ranged from 101.9 +/- 3.0 to 123.5 +/- 3.0 nm and - 35.1 +/- 0.5 to +34.6 +/- 2.3 mV, respectively.","Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17090399/),m,35.1,182788,DB01054,Nitrendipine
,1598834,flow rate,To increase life of the YWG-C18 column a mixture of methanol and 5 mmol.L-1 phosphate buffer (70:30 vol/vol) was selected as mobile phase with a flow rate of 0.8 ml.min-1.,[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ml] / [min],0.8,183331,DB01054,Nitrendipine
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),%,95-102,183332,DB01054,Nitrendipine
,1598834,recoveries,"The within-day and day-to-day precisions (CV) of this method were 4.5% and 7.0%, respectively, with recoveries of 95-102% (10-1000 ng.ml-1).",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[ng] / [ml],10-1000,183333,DB01054,Nitrendipine
,1598834,Vc,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg],6.3,183334,DB01054,Nitrendipine
,1598834,Cl,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[l] / [kg·min],0.021,183335,DB01054,Nitrendipine
,1598834,T1/2 alpha,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,30,183336,DB01054,Nitrendipine
,1598834,T1/2 beta,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),min,230,183337,DB01054,Nitrendipine
,1598834,AUC,"The parameters obtained were as follow: Vc 6.3 L.kg-1, Cl 0.021 L.kg-1.min-1, T1/2 alpha 30 min, T1/2 beta 230 min, AUC 102 micrograms.min.ml-1.",[Determination of m-nifedipine and its pharmacokinetic study in rabbits by high-pressure liquid chromatography]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1598834/),[min·μg] / [ml],102,183338,DB01054,Nitrendipine
,2753062,AUC (0-24),The AUC (0-24) and the elimination half-life of nitrendipine were significantly increased; the AUC (0-24) in patients with renal failure (median creatinine clearance 27.1 ml x min-1) was 196 ng x ml-1 x h compared to 97.8 ng x ml-1 x h in control subjects (median creatinine clearance 94.4 ml x min-1).,Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753062/),[h·ng] / [ml],196,185114,DB01054,Nitrendipine
,2753062,AUC (0-24),The AUC (0-24) and the elimination half-life of nitrendipine were significantly increased; the AUC (0-24) in patients with renal failure (median creatinine clearance 27.1 ml x min-1) was 196 ng x ml-1 x h compared to 97.8 ng x ml-1 x h in control subjects (median creatinine clearance 94.4 ml x min-1).,Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753062/),[h·ng] / [ml],97.8,185115,DB01054,Nitrendipine
,2753062,elimination half-lives,The corresponding elimination half-lives were 13.5 h in renal failure and 4.4 h in the controls.,Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753062/),h,13.5,185116,DB01054,Nitrendipine
,2753062,elimination half-lives,The corresponding elimination half-lives were 13.5 h in renal failure and 4.4 h in the controls.,Elimination and haemodynamic effects of nitrendipine in patients with chronic renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753062/),h,4.4,185117,DB01054,Nitrendipine
,21601538,flow rate,"The mobile phase was composed of acetonitrile-10 mmol/L ammonium acetate (75:25, v/v) with a flow rate of 0.20 mL/min.",Determination of nifedipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601538/),[ml] / [min],0.20,185587,DB01054,Nitrendipine
,21601538,run time,A high throughput was achieved with a run time of 1.4 min per sample.,Determination of nifedipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21601538/),[min] / [sample],1.4,185588,DB01054,Nitrendipine
,11250100,partition coefficient,The results of the in vitro erythrocyte partitioning experiments confirm this observations as the mean values of partition coefficient to erythrocytes was found to be 2.85 +/- 0.17.,The relevance of nitrendipine erythrocyte partitioning for the variability of its bioavailability parameters. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11250100/),,2.85,185796,DB01054,Nitrendipine
,14677769,apparent association constant,"The solubility of nitrendipine increased linearly as a function of HP-beta-CD concentration, resulting in AL-type phase solubility diagram which revealed a formation of inclusion complex in a molar ratio of 1:1, with the apparent association constant of 108.3M(-1).",Improvement of dissolution and bioavailability of nitrendipine by inclusion in hydroxypropyl-beta-cyclodextrin. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14677769/),1/[M],108.3,191829,DB01054,Nitrendipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,1.50,192764,DB01054,Nitrendipine
,9625273,tmax,Grapefruit juice postponed the tmax of diazepam from 1.50 h to 2.06 h (P < 0.01).,Interaction between grapefruit juice and diazepam in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9625273/),h,2.06,192765,DB01054,Nitrendipine
,24092617,C max,The mean C max was 0.034 ± 0.005 μg/mL (nitrendipine alone) and 0.054 ± 0.006 μg/mL (nitrendipine after pretreatment with silibinin).,Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092617/),[μg] / [ml],0.034,195703,DB01054,Nitrendipine
,24092617,C max,The mean C max was 0.034 ± 0.005 μg/mL (nitrendipine alone) and 0.054 ± 0.006 μg/mL (nitrendipine after pretreatment with silibinin).,Effect of silibinin on the pharmacokinetics of nitrendipine in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24092617/),[μg] / [ml],0.054,195704,DB01054,Nitrendipine
,1888628,bioavailability,3. Upon oral administration (tablet) the bioavailability of (S)-(-)-nitrendipine (13.4% +/- 5.6%) was 75% (50% - 98%) higher than that of (R)-nitrendipine (7.9% +/- 4.0%) (mean +/- s.d. (95% confidence interval)).,Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888628/),%,13.4,196358,DB01054,Nitrendipine
,1888628,bioavailability,3. Upon oral administration (tablet) the bioavailability of (S)-(-)-nitrendipine (13.4% +/- 5.6%) was 75% (50% - 98%) higher than that of (R)-nitrendipine (7.9% +/- 4.0%) (mean +/- s.d. (95% confidence interval)).,Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888628/),%,75,196359,DB01054,Nitrendipine
,1888628,bioavailability,3. Upon oral administration (tablet) the bioavailability of (S)-(-)-nitrendipine (13.4% +/- 5.6%) was 75% (50% - 98%) higher than that of (R)-nitrendipine (7.9% +/- 4.0%) (mean +/- s.d. (95% confidence interval)).,Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1888628/),%,7.9,196360,DB01054,Nitrendipine
,33751276,polydispersity index (PDI),The optimized NS showed a particle size of 505.74 ± 15.48 nm with a polydispersity index (PDI) of 0.083 ± 0.006.,Development of Nanonized Nitrendipine and Its Transformation into Nanoparticulate Oral Fast Dissolving Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33751276/),,0.083,202581,DB01054,Nitrendipine
,33751276,% NIT content,The % NIT content in the NCs was found to be 78.4 ± 2.3%.,Development of Nanonized Nitrendipine and Its Transformation into Nanoparticulate Oral Fast Dissolving Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33751276/),%,78.4,202582,DB01054,Nitrendipine
,33751276,dispersion,"The dispersion, wetting, and disintegration time of the optimized batch of N-ODT was found to be 39 ± 1.13 s, 44.66 ± 1.52 s, and 33.91 ± 0.94 s respectively.",Development of Nanonized Nitrendipine and Its Transformation into Nanoparticulate Oral Fast Dissolving Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33751276/),s,39,202583,DB01054,Nitrendipine
,33751276,wetting,"The dispersion, wetting, and disintegration time of the optimized batch of N-ODT was found to be 39 ± 1.13 s, 44.66 ± 1.52 s, and 33.91 ± 0.94 s respectively.",Development of Nanonized Nitrendipine and Its Transformation into Nanoparticulate Oral Fast Dissolving Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33751276/),s,44.66,202584,DB01054,Nitrendipine
,33751276,disintegration time,"The dispersion, wetting, and disintegration time of the optimized batch of N-ODT was found to be 39 ± 1.13 s, 44.66 ± 1.52 s, and 33.91 ± 0.94 s respectively.",Development of Nanonized Nitrendipine and Its Transformation into Nanoparticulate Oral Fast Dissolving Drug Delivery System. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33751276/),s,33.91,202585,DB01054,Nitrendipine
,3214442,terminal half-lives,"The radioactivity was eliminated from plasma with terminal half-lives of 57 (rat) and 188 h (dog) during an observation period up to 10 and 9 days, respectively.","The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214442/),h,57,211126,DB01054,Nitrendipine
,3214442,terminal half-lives,"The radioactivity was eliminated from plasma with terminal half-lives of 57 (rat) and 188 h (dog) during an observation period up to 10 and 9 days, respectively.","The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214442/),h,188,211127,DB01054,Nitrendipine
,3214442,bioavailability,The bioavailability of nitrendipine after oral administration amounted to 12% in rats and 29% in dogs due to a strong first pass elimination process.,"The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214442/),%,12,211128,DB01054,Nitrendipine
,3214442,bioavailability,The bioavailability of nitrendipine after oral administration amounted to 12% in rats and 29% in dogs due to a strong first pass elimination process.,"The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3214442/),%,29,211129,DB01054,Nitrendipine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,104,215212,DB01054,Nitrendipine
,3300758,Blood loss,Blood loss consequent on TOP did not differ in the two groups (nitrendipine 104 +/- 16 ml; placebo 114 +/- 20 ml).,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),ml,114,215213,DB01054,Nitrendipine
,3300758,time after ingestion to peak concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),min,105,215214,DB01054,Nitrendipine
,3300758,concentration,The median time after ingestion to peak concentration was 105 min; the median concentration was 7.8 ng ml-1.,"Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3300758/),[ng] / [ml],7.8,215215,DB01054,Nitrendipine
,10405773,plasma half-life,"The plasma half-life of amlodipine is as long as 36 h, while that of nitrendipine is 10 h.","Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405773/),h,36,216029,DB01054,Nitrendipine
,10405773,plasma half-life,"The plasma half-life of amlodipine is as long as 36 h, while that of nitrendipine is 10 h.","Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10405773/),h,10,216030,DB01054,Nitrendipine
,26375758,fluxes,Nitrendipine-loaded nanovesicles of ceramide-2 containing oleic acid (NOV-5) have shown fluxes in the range of 4.88-24.72 μg/cm(2)/h nitrendipine oral suspension (NOS) at equal dose.,Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26375758/),[μg] / [cm(2)·h],4.88-24.72,222049,DB01054,Nitrendipine
,8009887,apparent liver volume,The apparent liver volume for amlodipine was 920 ml compared with 38ml for nitrendipine.,Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009887/),ml,920,223996,DB01054,Nitrendipine
,8009887,apparent liver volume,The apparent liver volume for amlodipine was 920 ml compared with 38ml for nitrendipine.,Importance of metabolic stability and hepatic distribution to the pharmacokinetic profile of amlodipine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009887/),ml,38,223997,DB01054,Nitrendipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,371.35,225426,DB01054,Nitrendipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,270.20,225427,DB01054,Nitrendipine
,11589462,m/z,"For the quantification of the nisoldipine enantiomers a GC-MS with an Ultra 1 Hewlett-Packard column was used with the detector operated in the single-ion monitoring mode with electron-impact ionization (m/z 371.35 and 270.20 for nisoldipine and m/z 360.00 for the internal standard, nitrendipine).",Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,360.00,225428,DB01054,Nitrendipine
,11589462,AUC(0-24) (+)/(-) ratio,The enantioselective pilot study on the kinetic disposition of nisoldipine administered in the racemic form to a hypertensive patient using a multiple dose regimen revealed the accumulation of the (+)-enantiomer with an AUC(0-24) (+)/(-) ratio of approximately 8.,Enantioselective assay of nisoldipine in human plasma by chiral high-performance liquid chromatography combined with gas chromatographic-mass spectrometry: applications to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11589462/),,8,225429,DB01054,Nitrendipine
,1516607,S/R ratio of AUCs,"As an index of stereoselectivity, the mean S/R ratio of AUCs in control subjects (2.07) was not significantly different from the ratio in patients with CRF (2.68).",Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516607/),,2.07,236165,DB01054,Nitrendipine
,1516607,S/R ratio of AUCs,"As an index of stereoselectivity, the mean S/R ratio of AUCs in control subjects (2.07) was not significantly different from the ratio in patients with CRF (2.68).",Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1516607/),,2.68,236166,DB01054,Nitrendipine
,22579001,Km,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),μM,114.35,239835,DB01054,Nitrendipine
,22579001,Vmax,The Km and Vmax of indapamide metabolism were 114.35 ± 3.47 μM and 23.13 ± 6.61 μmol/g/min.,Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),[μM] / [g·min],23.13,239836,DB01054,Nitrendipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,82.6,239837,DB01054,Nitrendipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,72,239838,DB01054,Nitrendipine
,22579001,maximum inhibitory rates,"In addition, felodipine, nifedipine and nitrendipine significantly inhibited indapamide metabolism with the maximum inhibitory rates of 82.6%, 72% and 95%, respectively.",Effects of some antihypertensive drugs on the metabolism and pharmacokinetics of indapamide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22579001/),%,95,239839,DB01054,Nitrendipine
,2092581,bioavailability,"The bioavailability of A, C and D relative to B was 31.8%, 72.2% and 138.9% respectively.",[Studies on the bioavailability of nitrendipine tablet]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092581/),%,31.8,240516,DB01054,Nitrendipine
,2092581,bioavailability,"The bioavailability of A, C and D relative to B was 31.8%, 72.2% and 138.9% respectively.",[Studies on the bioavailability of nitrendipine tablet]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092581/),%,72.2,240517,DB01054,Nitrendipine
,2092581,bioavailability,"The bioavailability of A, C and D relative to B was 31.8%, 72.2% and 138.9% respectively.",[Studies on the bioavailability of nitrendipine tablet]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2092581/),%,138.9,240518,DB01054,Nitrendipine
,6085388,maximum concentration (Cmax),"On day 1, the maximum concentration (Cmax) in the normals was 4.67 +/- 2.60 ng/ml and in the hepatic patients 16.87 +/- 9.42 ng/ml.",Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[ng] / [ml],4.67,240542,DB01054,Nitrendipine
,6085388,maximum concentration (Cmax),"On day 1, the maximum concentration (Cmax) in the normals was 4.67 +/- 2.60 ng/ml and in the hepatic patients 16.87 +/- 9.42 ng/ml.",Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[ng] / [ml],16.87,240543,DB01054,Nitrendipine
,6085388,elimination half-life,The elimination half-life was only slightly prolonged from 15.29 +/- 7.25 h in the normals to 19.57 +/- 4.28 h in the hepatic impairment group.,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),h,15.29,240544,DB01054,Nitrendipine
,6085388,elimination half-life,The elimination half-life was only slightly prolonged from 15.29 +/- 7.25 h in the normals to 19.57 +/- 4.28 h in the hepatic impairment group.,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),h,19.57,240545,DB01054,Nitrendipine
,6085388,area under the concentration-time curve,This resulted in a marked increase in the area under the concentration-time curve from 28.71 +/- 28.92 ng . h/ml for the normals to 119.56 +/- 34.39 ng .,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),[h·ng] / [ml],28.71,240546,DB01054,Nitrendipine
,6085388,area under the concentration-time curve,This resulted in a marked increase in the area under the concentration-time curve from 28.71 +/- 28.92 ng . h/ml for the normals to 119.56 +/- 34.39 ng .,Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6085388/),ng,119.56,240547,DB01054,Nitrendipine
,2455147,AUC0-12,"Thus, AUC0-12 was 9.7 +/- 0.75 ng ml-1 h (X +/- SEM) when digoxin was given alone and was 11.2 +/- 0.92 ng ml-1 h under coadministration of the calcium antagonist (p less than 0.05).",Nitrendipine/digoxin interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455147/),[h·ng] / [ml],9.7,244124,DB01054,Nitrendipine
,2455147,AUC0-12,"Thus, AUC0-12 was 9.7 +/- 0.75 ng ml-1 h (X +/- SEM) when digoxin was given alone and was 11.2 +/- 0.92 ng ml-1 h under coadministration of the calcium antagonist (p less than 0.05).",Nitrendipine/digoxin interaction. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2455147/),[h·ng] / [ml],11.2,244125,DB01054,Nitrendipine
,2468855,area under the curve,"The area under the curve for Groups 1, 2, 3, and 4 was 50.5 +/- 19.4, 186 +/- 120, 107 +/- 49, and 88 +/- 43 ng h/ml, respectively (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),[h·ng] / [ml],50.5,244478,DB01054,Nitrendipine
,2468855,area under the curve,"The area under the curve for Groups 1, 2, 3, and 4 was 50.5 +/- 19.4, 186 +/- 120, 107 +/- 49, and 88 +/- 43 ng h/ml, respectively (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),[h·ng] / [ml],186,244479,DB01054,Nitrendipine
,2468855,area under the curve,"The area under the curve for Groups 1, 2, 3, and 4 was 50.5 +/- 19.4, 186 +/- 120, 107 +/- 49, and 88 +/- 43 ng h/ml, respectively (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),[h·ng] / [ml],107,244480,DB01054,Nitrendipine
,2468855,area under the curve,"The area under the curve for Groups 1, 2, 3, and 4 was 50.5 +/- 19.4, 186 +/- 120, 107 +/- 49, and 88 +/- 43 ng h/ml, respectively (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),[h·ng] / [ml],88,244481,DB01054,Nitrendipine
,2468855,elimination half-life,"Corresponding values of elimination half-life were 9.9 +/- 1.3, 20 +/- 6.5, 13.3 +/- 6.1, and 15.9 +/- 8.0 h (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),h,9.9,244482,DB01054,Nitrendipine
,2468855,elimination half-life,"Corresponding values of elimination half-life were 9.9 +/- 1.3, 20 +/- 6.5, 13.3 +/- 6.1, and 15.9 +/- 8.0 h (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),h,20,244483,DB01054,Nitrendipine
,2468855,elimination half-life,"Corresponding values of elimination half-life were 9.9 +/- 1.3, 20 +/- 6.5, 13.3 +/- 6.1, and 15.9 +/- 8.0 h (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),h,13.3,244484,DB01054,Nitrendipine
,2468855,elimination half-life,"Corresponding values of elimination half-life were 9.9 +/- 1.3, 20 +/- 6.5, 13.3 +/- 6.1, and 15.9 +/- 8.0 h (p less than 0.05).",The effects of age and race on nitrendipine pharmacokinetics and pharmacodynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2468855/),h,15.9,244485,DB01054,Nitrendipine
,22282953,m,Detection was performed by a triple-quadrupole mass spectrometry with positive electrospray ionization (ESI) as source ionization in multiple-reaction monitoring (MRM) mode at m/z 361.0 --> 315.0 for NTD and m/z 260.2 --> 116.0 for IS.,Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),,260.2,249764,DB01054,Nitrendipine
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,90.2,249765,DB01054,Nitrendipine
,22282953,extraction recoveries,"The mean extraction recoveries of NTD and IS were 90.2% and 82.4%, respectively.",Ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of nitrendipine in dog plasma and its application to a pharmacokinetic study of a solid self-emulsifying pellet formulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282953/),%,82.4,249766,DB01054,Nitrendipine
,3653225,"area under the plasma concentration-time curve, AUC (0-24),","After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[h·ng] / [ml],94.5,249828,DB01054,Nitrendipine
,3653225,plasma clearance CL,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[ml] / [min],1380.6,249829,DB01054,Nitrendipine
,3653225,AUC (0-24) h,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[h·ng] / [ml],309.4,249830,DB01054,Nitrendipine
,3653225,CL,"After chronic oral dosing, the area under the plasma concentration-time curve, AUC (0-24), was 94.5 ng ml-1 h and the plasma clearance CL was 1380.6 ml/min in the healthy controls; in patients with cirrhosis the AUC (0-24) h was significantly greater at 309.4 ng ml-1 h and CL had fallen to 686.6 ml/min.",Bioavailability and elimination of nitrendipine in liver disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3653225/),[ml] / [min],686.6,249831,DB01054,Nitrendipine
,2442513,elimination half-life,Determination of the plasma concentrations of felodipine during steady-state conditions showed a mean elimination half-life of 23.4 +/- 11.1 h.,Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2442513/),h,23.4,251896,DB01054,Nitrendipine
,16515896,analytical recovery,The analytical recovery from rat plasma was found to be 97.9+/-4.1% (n = 15).,Determination of rutin deca(H-) sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515896/),%,97.9,253096,DB01054,Nitrendipine
,16515896,LOD,"LOD and LOQ for RDS in plasma were calculated to be 0.12 nmol/mL and 0.30+/-0.024 nmol/mL (R.S.D. = 8.2%, n = 5), respectively.",Determination of rutin deca(H-) sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515896/),[nM] / [ml],0.12,253097,DB01054,Nitrendipine
,16515896,LOQ,"LOD and LOQ for RDS in plasma were calculated to be 0.12 nmol/mL and 0.30+/-0.024 nmol/mL (R.S.D. = 8.2%, n = 5), respectively.",Determination of rutin deca(H-) sulfate sodium in rat plasma using ion-pairing liquid chromatography after ion-pairing solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16515896/),[nM] / [ml],0.30,253098,DB01054,Nitrendipine
,8223833,terminal elimination half-life,The terminal elimination half-life (4.1 h in the dialysis patients and 3.6 h in non-dialysis patients) was similar to that observed in patients with normal renal function.,Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223833/),h,4.1,261489,DB01054,Nitrendipine
,8223833,terminal elimination half-life,The terminal elimination half-life (4.1 h in the dialysis patients and 3.6 h in non-dialysis patients) was similar to that observed in patients with normal renal function.,Pharmacodynamics and pharmacokinetics of oral nitrendipine solution in hypertensive patients with advanced renal failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8223833/),h,3.6,261490,DB01054,Nitrendipine
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,61.4,263302,DB01054,Nitrendipine
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,51.5,263303,DB01054,Nitrendipine
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,29.4,263304,DB01054,Nitrendipine
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,26.7,263305,DB01054,Nitrendipine
,20585842,absolute bioavailability,"From the simulated T(50%) values (50% dissolution time), the dissolution rates of crystals with particle sizes of 200 nm, 620 nm, 2.7 microm, 4.1 microm and 20.2 microm were calculated to be 5.1 x 10(4), 1.0 x 10(4), 237, 64 and 11-fold greater than that of the raw crystals and resulted in absolute bioavailability of 61.4% 51.5%, 29.4%, 26.7%, 24.7%, respectively.",Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20585842/),%,24.7,263306,DB01054,Nitrendipine
,2900404,oral bioavailability,"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,15,266162,DB01054,Nitrendipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],1.6,266163,DB01054,Nitrendipine
,2900404,peak concentration,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[nM] / [l],8.9,266164,DB01054,Nitrendipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],2.0,266165,DB01054,Nitrendipine
,2900404,area under the curve,"Plasma felodipine concentrations after a 5 mg oral dose were grossly reduced in the epileptic patients: the mean peak concentration was 1.6 (vs 8.9) nmol/l, and the area under the curve was only 2.0 (vs 30.0) nmol.h/l.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),[h·nM] / [l],30.0,266166,DB01054,Nitrendipine
,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,6.6,266167,DB01054,Nitrendipine
less,2900404,relative bioavailability,"The relative bioavailability of felodipine in the epileptic patients was thus only 6.6% of that in the normal subjects, and less than 1% of the oral dose was systemically available.",Reduced felodipine bioavailability in patients taking anticonvulsants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2900404/),%,1,266168,DB01054,Nitrendipine
,2753065,Cmax,"The mean peak plasma concentration normalized to a dose of 10 mg (Cmax 46 nmol/l) was twice as high in the cirrhotic patients as in the healthy subjects, but the bioavailability, f, (17.0%) was comparable.",Pharmacokinetics of felodipine in patients with liver disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753065/),[nM] / [l],46,271281,DB01054,Nitrendipine
,2753065,"bioavailability, f","The mean peak plasma concentration normalized to a dose of 10 mg (Cmax 46 nmol/l) was twice as high in the cirrhotic patients as in the healthy subjects, but the bioavailability, f, (17.0%) was comparable.",Pharmacokinetics of felodipine in patients with liver disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2753065/),%,17.0,271282,DB01054,Nitrendipine
,21495269,flow rate,"The mobile phase was consisted of acetonitrile-5 mM ammonium acetate (52:48, v/v), delivered at flow rate of 1 mL/min.",Bioequivalence of nifedipine softgel and capsule in healthy Chinese volunteers by liquid chromatography-mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21495269/),[ml] / [min],1,271762,DB01054,Nitrendipine
